M
Mark P Saunders
Researcher at National Health Service
Publications - 125
Citations - 5661
Mark P Saunders is an academic researcher from National Health Service. The author has contributed to research in topics: Colorectal cancer & Capecitabine. The author has an hindex of 29, co-authored 109 publications receiving 4308 citations. Previous affiliations of Mark P Saunders include Churchill Hospital & University of Chicago.
Papers
More filters
Journal ArticleDOI
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
Maxime J M van der Valk,Maxime J M van der Valk,Denise E. Hilling,Denise E. Hilling,Esther Bastiaannet,Elma Meershoek-Klein Kranenbarg,Geerard L. Beets,Geerard L. Beets,Nuno Figueiredo,Angelita Habr-Gama,Rodrigo Oliva Perez,Andrew G Renehan,Andrew G Renehan,Cornelis J.H. van de Velde,Madeleine Ahlberg,Ane L Appelt,Oktar Asoglu,Maria-Theresa Bär,Rita Barroca,Regina G. H. Beets-Tan,Eric Belgers,Robbert J I Bosker,Stephanie O. Breukink,Krysztof Bujko,Carlos Carvalho,Christopher M. Cunningham,Ben Creavin,André D’Hoore,Jean-Pierre Gerard,Simon Gollins,Christiaan Hoff,Fabian A. Holman,Britt J. P. Hupkens,Soledad Iseas,Anders Jakobsen,Amir Keshvari,Sietze A Koopal,Miranda Kusters,Melanie Langheinrich,Jeroen W. A. Leijtens,Monique Maas,Lee Malcomson,Zamam Z Mamedli,Anna Martling,Klaus E. Matzel,Jarno Melenhorst,María L Morici,Sthela M. Murad-Regadas,Sarah T O'Dwyer,Koen C.M.J. Peeters,Isadora Rosa,Gustavo Rossi,Harm J. T. Rutten,Fernando Sanchez Loria,Marit E van der Sande,Guilherme Pagin São Julião,Mark P Saunders,Arthur Sun Myint,Hedwig van der Sluis,Renaud Schiappa,Nigel Scott,Jan H.M.B. Stoot,A Koen Talsma,Isabelle Terrasson,Handan Tokmak,Carlos A. Vaccaro,Alexander L Vahrmeijer,Daria K Wasowicz,Henderik L Westreenen,Des C. Winter,Albert Wolthuis,David D. E. Zimmerman +71 more
TL;DR: This dataset has the largest series of patients with rectal cancer treated with a W&W approach, consisting of approximately 50% data from previous cohort series and 50% unpublished data.
Journal ArticleDOI
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial
Roger D James,Rob Glynne-Jones,Helen Meadows,David Cunningham,Arthur Sun Myint,Mark P Saunders,Tim Maughan,Alec McDonald,Sharadah Essapen,Martin Leslie,Stephen Falk,Charles Wilson,Simon Gollins,Rubina Begum,Jonathan A. Ledermann,Latha Kadalayil,David Sebag-Montefiore +16 more
TL;DR: The results of this trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fractions should remain standard practice in the UK.
Journal ArticleDOI
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis
Andrew G Renehan,Lee Malcomson,Richard Emsley,Simon Gollins,Andrew Maw,Arthur Sun Myint,Paul S Rooney,Shabbir Susnerwala,Anthony Blower,Mark P Saunders,Malcolm S Wilson,Nigel Scott,Sarah T O'Dwyer +12 more
TL;DR: Comparing oncological outcomes between patients managed by watch and wait who achieved a clinical complete response and those who had surgical resection to address the shortage of evidence regarding the safety of the watch-and-wait approach is addressed.
Journal ArticleDOI
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham,István Láng,Eugenio Marcuello,Vito Lorusso,Janja Ocvirk,Dong Bok Shin,Derek J. Jonker,S. Osborne,Niko Andre,Daniel Waterkamp,Mark P Saunders +10 more
TL;DR: The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer.
Journal ArticleDOI
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt,Kate Wilson,Val Gebski,Michelle M. Cummins,Diana Zannino,Guy van Hazel,Guy van Hazel,Bridget A. Robinson,Bridget A. Robinson,A. Broad,A. Broad,Vinod Ganju,Vinod Ganju,Stephen P. Ackland,Garry Forgeson,David Cunningham,David Cunningham,Mark P Saunders,Martin R. Stockler,YuJo Chua,John Zalcberg,R. John Simes,Timothy J. Price +22 more
TL;DR: Adding bevacizumab to capecitabine, with or without mitomycin, significantly improves PFS without major additional toxicity or impairment of QOL.